Arrowhead Pharmaceuticals reported that ARO-MAPT was generally well tolerated in healthy volunteers, with no serious adverse events, deaths, or toxicity-related study dropouts, and mild reported side effects including injection site reactions, vessel puncture bruising, respiratory infections, and headaches.

From the articleArrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data dropAlso in Arrowhead reports positive interim data for Alzheimer’s drug By Investing.com, Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit